Drug Trial Begins Targeting Mitochondrial Diseases - Dr. Guy Miller - 7/15/08

<p><span data-sheets-value="{&quot;1&quot;:2,&quot;2&quot;:&quot;Exclusive Interview with Dr. Guy Miller, CEO of Edison Pharma.&quot;}" data-sheets-userformat="{&quot;2&quot;:15169,&quot;3&quot;:{&quot;1&quot;:0},&quot;9&quot;:0,&quot;11&quot;:4,&quot;12&quot;:0,&quot;14&quot;:[null,2,0],&quot;15&quot;:&quot;Arial, Helvetica, sans-serif&quot;,&quot;16&quot;:11}">Exclusive Interview with Dr. Guy Miller, CEO of Edison Pharma.</span></p> <p>Is there hope for a cure for Mitochondrial Disease? Perhaps the answer is closer than we thought.</p> <p>On July 15, 2008 Edison Pharma and partner Penwest Pharmaceuticals announced that A0001, an &ldquo;improved&rdquo; variant of Coenzyme Q10 (CoQ10), has entered Phase 1 clinical development with healthy volunteers. Edison predicts trials in patients with inherited mitochondrial disease will begin in 2009.</p>